Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19
Suchitra Kamle, … , Chun Geun Lee, Jack A. Elias
Suchitra Kamle, … , Chun Geun Lee, Jack A. Elias
Published November 8, 2021
Citation Information: JCI Insight. 2021;6(21):e148749. https://doi.org/10.1172/jci.insight.148749.
View: Text | PDF
Research Article COVID-19 Therapeutics

Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19

  • Text
  • PDF
Abstract

COVID-19 is caused by SARS-CoV-2 (SC2) and is more prevalent and severe in elderly and patients with comorbid diseases (CM). Because chitinase 3-like-1 (CHI3L1) is induced during aging and CM, the relationships between CHI3L1 and SC2 were investigated. Here, we demonstrate that CHI3L1 is a potent stimulator of the SC2 receptor angiotensin converting enzyme 2 (ACE2) and viral spike protein priming proteases (SPP), that ACE2 and SPP are induced during aging, and that anti-CHI3L1, kasugamycin, and inhibitors of phosphorylation abrogate these ACE2- and SPP-inductive events. Human studies also demonstrate that the levels of circulating CHI3L1 are increased in the elderly and patients with CM, where they correlate with COVID-19 severity. These studies demonstrate that CHI3L1 is a potent stimulator of ACE2 and SPP, that this induction is a major mechanism contributing to the effects of aging during SC2 infection, and that CHI3L1 co-opts the CHI3L1 axis to augment SC2 infection. CHI3L1 plays a critical role in the pathogenesis of and is an attractive therapeutic target in COVID-19.

Authors

Suchitra Kamle, Bing Ma, Chuan Hua He, Bedia Akosman, Yang Zhou, Chang-Min Lee, Wafik S. El-Deiry, Kelsey Huntington, Olin Liang, Jason T. Machan, Min-Jong Kang, Hyeon Jun Shin, Emiko Mizoguchi, Chun Geun Lee, Jack A. Elias

×

Figure 2

CHI3L1 stimulates ACE2 and SPP in vitro and enhances S protein processing and cellular integration.

Options: View larger image (or click on image) Download as PowerPoint
CHI3L1 stimulates ACE2 and SPP in vitro and enhances S protein processin...
(A) Calu-3 lung epithelial cells were incubated with the noted concentrations of recombinant CHI3L1 (rCHI3L1; ng/mL) or vehicle control (rCHI3L1 = 0) for 24 hours and were then subjected to RT-qPCR to quantitate the levels of mRNA encoding ACE2 and the SPP. (B) Western blot evaluations of the dose response and kinetics of CHI3L1 stimulation of ACE2 and SPP protein accumulation in Calu-3 cells. (C and D) Calu-3 cells were incubated with vehicle (PBS; CHI3L1–) or rCHI3L1 (500 ng/mL) for 24 hours, recombinant S protein of SC2 was added, and the incubation continued for an additional 2 hours. The cell lysates were prepared, Co-IP and immunoblot assays were undertaken (C), and the uncleaved S and cleaved S1 and S2 proteins were evaluated using Western immunoblotting (D). (E) Calu-3 cells were incubated with vehicle (rCHI3L1–) or the noted concentrations of rCHI3L1 for 24 hours. They were then transfected with a pseudovirus containing the S protein (PS; D614 variant) from SC2 and a GFP expression construct and incubated for additional 24 hours and then evaluated using fluorescence microscopy. Quantification of mean fluorescence intensity (MFI) can be seen in the dot plot on the right. (F) Calu-3 cells were incubated with rCHI3L1 or vehicle control for 48 hours in the presence or absence of antibody against CHI3L1 (FRG) or control antibody (IgG). Pseudovirus S (PS; D614 and G614 variants) that expressed GFP was added as noted, and GFP-positive cells (%) were evaluated by flow cytometry. Values in A and E are mean ± SEM. B–F are the representative data obtained from at least 3 independent experiments. β-Actin or GAPDH was used as an internal control. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (1-way ANOVA with post hoc Dunnett’s multiple comparison test). Scale bar: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts